Browsing by Author Buzon, Maria

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2016Broad activation of latent HIV-1 in vivoBarton, Kirston; Byth Wilson, Karen; Hiener, Bonnie; Palmer, Sarah; Winckelmann, Anni; Buzon, Maria; Denton, Paul; et al, Various; Harrington, Sean; Lanfear, Robert; Lichterfeld, M; McMahon, James; Rasmussen, Thomas; Shao, Wei; Solomon, Ajantha; Western Clinical School: Westmead Institute for Medical Res; NH&MRC Clinical Trials Centre; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical ResBroad activation of latent HIV-1 in vivo, Nature Communications, vol.7, N/A, 2016,pp 1-8
2015Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostatPalmer, Sarah; Bashirova, Arman; Brinkmann, Christel; Buzon, Maria; Carrington, Mary; et al, Various; Olesen, Rikke; Ouyang, Zhengyu; Rasmussen, Thomas; Sogaard, Ole Schmeltz; Vigano, Selena; Yu, Xu; Western Clinical School: Westmead Institute for Medical ResInnate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat, Journal of Virology, vol.89, 20, 2015,pp 10176-10189
2014Panobinostat, a histone deacetylase inhibitor, for latent virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trialPalmer, Sarah; Brinkmann, Christel; Buzon, Maria; Dinarello, Charles A.; Erikstrup, Christian; Lewin, Sharon; Lichterfeld, Mathias; Olesen, Rikke; Ostergaard, Lars; Rasmussen, Thomas; Sogaard, Ole Schmeltz; Solomon, Ajantha; Tolstrup, Martin; Winckelmann, Anni A.; Western Clinical School: Westmead Millennium InstitutePanobinostat, a histone deacetylase inhibitor, for latent virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1/2, single group, clinical trial, The Lancet HIV, vol.1, 1, 2014,pp e13-e21